组织miR-219 miR-34a DCST1-AS1与非小细胞肺癌临床病理特征相关性及诊断价值  

Correlation of Tissue MiR-219 MiR-34a and DCST1-AS1 with the Clinicopathological Features in Non-small Cell Lung Cancer and its Diagnostic Value

作　　者：李晓琴 李月 刘玉兰 于映红 胡婕 陈仕高 程双华 LI Xiaoqin;LI Yue;LIU Yulan(Nuclear Industry 416 Hospital,the Second Affiliated Hospital of Chengdu Medical College,Sichuan Chengdu 610057,China)

机构地区：[1]成都医学院第二附属医院核工业四一六医院病理科,四川成都610057

出　　处：《河北医学》2025年第2期291-296,共6页Hebei Medicine

基　　金：2022年四川省医学(青年创新)科研课题,(编号:Q22060)。

摘　　要：目的:探讨组织微小核糖核苷酸-219(miR-219)、微小核糖核苷酸-34a(miR-34a)、DC-STAMP结构域1-反义1(DCST1-AS1)与非小细胞肺癌(NSCLC)临床病理特征相关性及诊断价值。方法:选取2022年5月至2024年5月核工业四一六医院收治的120例NSCLC患者,取其癌组织及癌旁组织,采用qRT-PCR法测定癌组织和癌旁组织miR-219、miR-34a、DCST1-AS1,比较不同临床病理特征患者组织miR-219、miR-34a、DCST1-AS1表达,Spearman相关系数分析组织miR-219、miR-34a、DCST1-AS1表达与临床病理特征相关性,采用受试者工作特征曲线(ROC)及曲线下面积(AUC)、决策曲线(DCA)分析组织miR-219、miR-34a、DCST1-AS1诊断NSCLC价值及临床净获益。结果:研究对象癌组织miR-219表达(0.68±0.20)低于癌旁组织(1.00±0.30),miR-34a、DCST1-AS1(1.31±0.39、1.39±0.42)表达高于癌旁组织(1.00±0.28、1.05±0.31)(t=9.722、7.073、7.135,P<0.05);TNM分期、肿瘤分化程度、淋巴结转移与组织miR-219(r=-0.644、0.650、-0.601)、miR-34a(r=0.613、-0.604、0.627)、DCST1-AS1(r=0.605、-0.620、0.616)表达相关(P<0.05);miR-219、miR-34a、DCST1-AS1联合诊断NSCLC的AUC为0.934(0.895~0.962),在范围0.2~1.0内,临床净获益率最高。结论:组织miR-219、miR-34a、DCST1-AS1表达与NSCLC患者临床病理特征密切相关,三者联合可作为诊断NSCLC的可靠方案,为临床精准诊治提供客观依据。Objective:To explore the correlation between tissue microRNA-219(miR-219),microRNA-34a(miR-34a),and DC-STAMP domain containing 1-antisense 1(DCST1-AS1)with the clinicopathological features in non-small cell lung cancer(NSCLC),as well as their diagnostic value.Methods:A total of 120 NSCLC patients admitted to the Nuclear Industry 416 Hospital from May 2022 to May 2024 were enrolled.The cancerous tissues and adjacent tissues were taken,and the expression of miR-219,miR-34a,and DCST1-AS1 in the cancerous tissues and adjacent tissues was determined by quantitative reverse-transcription polymerase chain reaction(qRT-PCR).The expression of miR-219,miR-34a,and DCST1-AS1 in patients with different clinicopathological features was compared.Spearman correlation coefficient analysis was used to analyze the correlation between the expression of miR-219,miR-34a,and DCST1-AS1 in tissues and clinicopathological features.Receiver operating characteristic(ROC)curve,area under the curve(AUC),and decision curve analysis(DCA)were used to analyze the diagnostic value and clinical net benefit of miR-219,miR-34a,and DCST1-AS1 in NSCLC.Results:The expression of miR-219(0.68±0.20 vs 1.00±0.30)in the cancerous tissue of the study subjects was significantly lower than that in the adjacent tissue,while the expressions of miR-34a(1.31±0.39 vs 1.00±0.28)and DCST1-AS1(1.39±0.42 vs 1.05±0.31)were significantly higher than those in the adjacent tissue(t=9.722,7.073,7.135,P<0.05).The tumor,node,metastasis(TNM)staging,tumor differentiation,and lymph node metastasis were closely associated with the expression of tissue miR-219(r=-0.644,0.650,-0.601),miR-34a(r=0.613,-0.604,0.627),and DCST1-AS1(r=0.605,-0.620,0.616)(P<0.05).The AUC of the combined diagnosis of miR-219,miR-34a,and DCST1-AS1 for NSCLC was 0.934(0.895-0.962),with the highest clinical net benefit rate within the range of 0.2~1.0.Conclusion:Tissue miR-219,miR-34a,and DCST1-AS1 expression are closely associated with clinicopathological features of NSCLC patients.The combination of th

关 键 词：非小细胞肺癌 临床病理特征 微小核糖核苷酸-219 微小核糖核苷酸-34a DC-STAMP结构域1-反义1 

分 类 号：R734.2[医药卫生—肿瘤]